Literature DB >> 10470773

Clinical gram-positive sepsis: does it fundamentally differ from gram-negative bacterial sepsis?

S M Opal1, J Cohen.   

Abstract

OBJECTIVE: To review the basic differences between gram-positive and gram-negative sepsis and to assess the effect of these differences on current and future therapeutic strategies for sepsis.
DESIGN: Literature review of the past 30 yrs of laboratory and clinical reports that analyze the microbial aspects of sepsis and the immunologic response to systemic infection.
RESULTS: The increasing prevalence of sepsis from gram-positive bacterial pathogens necessitates reevaluation of many of the basic assumptions about the molecular pathogenesis of septic shock. It has been assumed that the initiation of the systemic inflammatory response with activation of the proinflammatory cytokine networks and other mediators results in a similar pathophysiologic process, regardless of the causative microbic pathogen. Yet, there is increasing experimental evidence that fundamental differences exist in the host response to gram-positive bacterial pathogens compared with the host response to gram-negative organisms. Systemic immune activation during sepsis may promote the clearance of the microbic pathogen; however, generalized inflammation also contributes to the pathogenesis of septic shock. The balance between these beneficial and deleterious effects may differ between gram-positive and gram-negative pathogens.
CONCLUSIONS: Results of antimediator therapies in clinical trials in septic shock are inconclusive but suggest that the response may differ, depending on the type of microbic pathogen. The immune-mediated pathophysiologic mechanisms that underlie gram-positive sepsis and the potential interactions between the infecting microorganism and efficacy of anticytokine therapies require further investigation. Treatment strategies that explain the causative organism may be necessary for optimal use of immunoadjuvants in the future.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10470773     DOI: 10.1097/00003246-199908000-00039

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  51 in total

Review 1.  The difficulties of clinical trials evaluating therapeutic agents in patients with severe sepsis.

Authors:  T C Hall; D K Bilku; D Al-Leswas; C Horst; A R Dennison
Journal:  Ir J Med Sci       Date:  2011-11-08       Impact factor: 1.568

2.  Incidence of sepsis in hospitalized patients.

Authors:  Rui Moreno; Susana Afonso; Teresa Fevereiro
Journal:  Curr Infect Dis Rep       Date:  2006-09       Impact factor: 3.725

Review 3.  Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target.

Authors:  Kenneth L Becker; Richard Snider; Eric S Nylen
Journal:  Br J Pharmacol       Date:  2009-11-27       Impact factor: 8.739

Review 4.  Scientific and clinical challenges in sepsis.

Authors:  Luis Ulloa; Michael Brunner; Laura Ramos; Edwin A Deitch
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

Review 5.  Healthcare disparities in critical illness.

Authors:  Graciela J Soto; Greg S Martin; Michelle Ng Gong
Journal:  Crit Care Med       Date:  2013-12       Impact factor: 7.598

Review 6.  Sepsis pathophysiology and anesthetic consideration.

Authors:  Koichi Yuki; Naoka Murakami
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2015

Review 7.  Macrophages are important mediators of either tumor- or inflammation-induced lymphangiogenesis.

Authors:  Rui-Cheng Ji
Journal:  Cell Mol Life Sci       Date:  2011-10-08       Impact factor: 9.261

8.  Staphylococcal enterotoxin A-induced hepatotoxicity is predominantly mediated by Fas ligand (CD95L).

Authors:  Daniel Klintman; Xiang Li; Tohru Sato; Yusheng Wang; Bengt Jeppsson; Henrik Thorlacius
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

Review 9.  The response of the host microcirculation to bacterial sepsis: does the pathogen matter?

Authors:  Matthieu Legrand; Eva Klijn; Didier Payen; Can Ince
Journal:  J Mol Med (Berl)       Date:  2010-01-30       Impact factor: 4.599

10.  Effects of the TLR2 agonists MALP-2 and Pam3Cys in isolated mouse lungs.

Authors:  Martina Barrenschee; Dennis Lex; Stefan Uhlig
Journal:  PLoS One       Date:  2010-11-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.